In recent years, the third generation of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) developed by AstraZeneca has been used in the treatment of the NSCLC with the EGFR gene mutation. This evidence concerns the gene EGFR and non-small cell lung carcinoma.